In this BioPharma Boardroom interview, Matt Paterson, Chief Strategy Officer at Quotient Sciences, explores how AI is transforming pharmaceutical development, from accelerating formulation design to enhancing decision-making and reducing development timelines.
Why AI Will Be a Key Differentiator in Future CDMO Partnerships
He discusses the evolving role of CDMOs as strategic partners, the importance of combining AI with scientific expertise, and how sponsors can adopt innovative technologies while maintaining regulatory confidence and data integrity.
Read the full article on BioPharma Boardroom website here.